-

AOP Health congratulates FROM on its great scientific work in the field of myeloproliferative neoplasms

VIENNA--(BUSINESS WIRE)--Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) announced the publication of the latest results from the LOW-PV trial in the NEJM Evidence.

The findings support a paradigm shift in the treatment of patients with Polycythaemia Vera, a rare kind of blood cancer. AOP Orphan Pharmaceuticals GmbH (AOP Health) congratulates Prof. Tiziano Barbui and his team on this success and is pleased to have contributed to FROM’s important work as a reliable research partner.

Find out more about the trial and its results here.

About AOP Health

The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (“AOP Health”). The AOP Health Group is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the Group has become an established provider of integrated therapy solutions operating from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. The claim “Needs. Science. Trust.” sums up the foundation of the Group’s success: establishing trust through a continually high level of investment in research and development and a highly consistent and pragmatic orientation towards the needs of all stakeholders – especially the patients and their families as well as the healthcare professionals treating them.

Contacts

Further inquiry
DI Isolde Fally
Isolde.Fally@aop-health.com
+43-676-500 4048

Industry:

AOP Health Group

Release Versions
EnglishSpanishPortugueseGermanFrenchItalian (Summary)Dutch (Summary)Chinese TraditionalChinese SimplifiedJapanese

Contacts

Further inquiry
DI Isolde Fally
Isolde.Fally@aop-health.com
+43-676-500 4048

Social Media Profiles
LinkedIn AOP Health
More News From AOP Health Group

ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

VIENNA--(BUSINESS WIRE)--Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in AOP Health’s favor. At the heart of the case were reciprocal claims for damages arising from a dispute regarding a licensing agreement between the parties. The product in dispute The conflict centers around ropeginterferon alfa-2b, a substance la...

U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

VIENNA--(BUSINESS WIRE)--AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for RapiblykTM (landiolol) in the hospital critical care setting for the treatment of the severe heart condition supraventricular tachycardia (atrial fibrillation and atrial flutter). The approval is based on clinical studies which demonstrated that RapiblykTM (landiolol) enables rapid management of the heart...

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

VIENNA--(BUSINESS WIRE)--AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid tumors and lymphomas. This development program builds on AOP Health’s proven success in delivering cancer stem cell targeting ag...
Back to Newsroom